- Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2]
- ZYMFENTRA® is the first and only FDA-approved subcutaneous infliximab
- Late-breaking post hoc analysis of the LIBERTY studies suggests no meaningful differences in efficacy and safety outcomes at week 54 and 102 weeks between monotherapy and combination therapy of SC infliximab with immunosuppressants[3]
JERSEY CITY, N.J., Oct. 29, 2024
- Celltrion USA today announced a late-breaking post hoc analysis of the
pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb),
during the American College of Gastroenterology (ACG) 2024 Annual Scientific
Meeting. The data demonstrate that clinical outcomes for patients treated with
ZYMFENTRA monotherapy were comparable to those for patients on combination
therapy with immunosuppressants (IS), suggesting that monotherapy could be a
potential treatment option for patients with inflammatory bowel disease (IBD).[3] One-year
data for the LIBERTY studies were originally published in the journal Gastroenterology.[4]
ZYMFENTRA, the first and only FDA-approved
subcutaneous infliximab, had previously shown superior efficacy over placebo
for maintenance therapy in patients with Crohn's disease (CD) and ulcerative
colitis (UC) in the randomized LIBERTY-CD and LIBERTY-UC studies.[1],
[2] The new post hoc analysis explored the impact of baseline IS use
by comparing outcomes between monotherapy and combination therapy.[3]
The analysis included 429 patients from
the CD and UC cohorts across the LIBERTY studies (192 patients with CD
[monotherapy, n=126; combination therapy, n=66] and 237 patients with UC
[monotherapy, n=180; combination therapy, n=57]). In both studies, there were
no meaningful differences in efficacy outcomes between monotherapy and
combination therapy at Week 54 or Week 102, despite combination therapy
generally showing higher mean trough levels of infliximab after Week 10.
Additionally, the overall safety profile was comparable between monotherapy and
combination therapy throughout the pooled maintenance and extension phase.[3]
"The new data strengthens the case
for ZYMFENTRA monotherapy as a potential treatment option for patients
with Crohn's disease and ulcerative colitis," said Hetal Patel, PharmD
MBA, Head of Medical Affairs at Celltrion USA. "At Celltrion, we
are committed to offering therapies that help patients and healthcare providers
make informed, personalized treatment decisions. These findings suggest that
ZYMFENTRA could offer flexibility in treatment approaches, providing
confidence in monotherapy as an alternative to combination therapy, while
maintaining effective disease control."
About Celltrion USA
Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has five biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd) and YUFLYMA®(adalimumab-aaty) as well as a new biologic ZYMFENTRA®. Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit: www.celltrionusa.com.
About ZYMFENTRA® (infliximab-dyyb)
ZYMFENTRA is a prescription medicine used
as an injection under the skin (subcutaneous injection) by adults for the
maintenance treatment of: Moderately to severely active ulcerative colitis
following treatment with an infliximab product given by intravenous infusion
(IV) and moderately to severely active Crohn's disease following treatment
with an infliximab product given by intravenous infusion (IV). ZYMFENTRA blocks
the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be
overproduced in response to certain diseases and cause the immune system to
attack normal, healthy parts of the body.
ZYMFENTRA (infliximab-dyyb) was approved
by the FDA through the Biologics License Application (BLA) under the 351 (a)
pathway of the Public Health Service Act (a "stand-alone" BLA).
ZYMFENTRA is a self-injected form of infliximab and thus will be under patent
protection for its dosage form by 2037 and for its route of administration by
2040.
ZYMFENTRA® (infliximab-dyyb) U.S. Use and
Important Safety Information
ZYMFENTRA is a prescription medicine indicated in adults for maintenance
treatment of:
- Moderately to severely active Crohn's disease following treatment with an infliximab product administered intravenously.
- Moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously.
It is not known if ZYMFENTRA is safe and effective in
children under 18 years of age.
What is the most important information I
should know about ZYMFENTRA?
SERIOUS INFECTIONS
Patients treated with ZYMFENTRA are at
increased risk for developing serious infections involving various organ
systems and sites that may lead to hospitalization or death. Discontinue
ZYMFENTRA if a patient develops a serious infection or sepsis.
Reported infections include:
- Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before and during treatment with ZYMFENTRA. Treatment for latent infection should be initiated prior to treatment with ZYMFENTRA.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.
The risks and benefits of treatment with ZYMFENTRA should
be carefully considered prior to initiating therapy in patients with chronic or
recurrent infection. Closely monitor patients for the development of signs and
symptoms of infection during and after treatment with ZYMFENTRA, including the
possible development of TB in patients who tested negative for latent TB
infection prior to initiating therapy.
Risk of infection may be higher in patients greater than 65 years of age,
patients with comorbid conditions and/or patients taking concomitant
immunosuppressant therapy. In clinical trials, other serious infections
observed in patients treated with infliximab included arthritis bacterial,
pneumonia, and urinary tract infection.
MALIGNANCIES
Malignancies, some fatal, have been
reported in children, adolescents, and young adults treated with TNF blockers,
including infliximab products.
Approximately half of these cases were lymphomas, including Hodgkin's and
non-Hodgkin's lymphoma. The other cases represented a variety of malignancies,
including rare malignancies that are usually associated with immunosuppression
and malignancies that are not usually observed in children and adolescents. The
malignancies occurred after a median of 30 months after the first dose of
therapy. Most of the patients were receiving concomitant immunosuppressants.
Post-marketing cases of hepatosplenic T-cell lymphoma, a
rare type of T-cell lymphoma, have been reported in patients treated with TNF
blockers, including infliximab products. These cases have had a very aggressive
disease course and have been fatal. The majority of reported cases have
occurred in patients with Crohn's disease or ulcerative colitis, and most were
in adolescent and young adult males. Almost all of these patients had received
treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF
blocker at or prior to diagnosis. Carefully assess the risks and benefits of
treatment with ZYMFENTRA, especially in these patient types.
In clinical trials of all TNF blockers, more cases of malignancies were
observed compared with controls and the expected rate in the general
population. In clinical trials of some TNF blockers, including infliximab
products, more cases of other malignancies were observed compared with
controls. As the potential role of TNF blocker therapy in the development of
malignancies is not known, caution should be exercised when considering
treatment of patients with a current or a past history of malignancy.
Melanoma and Merkel cell carcinoma have
been reported in patients treated with TNF blocker therapy, including
infliximab products. Periodic skin examination is recommended for all patients,
particularly those with risk factors for skin cancer.
CONTRAINDICATIONS
ZYMFENTRA is contraindicated in patients with a previous severe
hypersensitivity reaction to infliximab-dyyb, other infliximab products, any of
the inactive ingredients of ZYMFENTRA or any murine proteins (severe
hypersensitivity reactions have included anaphylaxis, hypotension, and serum
sickness).
HEPATITIS B VIRUS REACTIVATION
TNF blockers, including infliximab products, have been associated with
reactivation of hepatitis B virus (HBV) in patients who are chronic carriers.
Some cases were fatal. Patients should be tested for HBV infection before
initiating ZYMFENTRA. For patients who test positive, consult a physician with
expertise in the treatment of hepatitis B. Exercise caution when prescribing
ZYMFENTRA for patients identified as carriers of HBV, and monitor closely for
active HBV infection during and following termination of therapy with
ZYMFENTRA. Discontinue ZYMFENTRA in patients who develop HBV reactivation and
initiate antiviral therapy with appropriate supportive treatment. Exercise
caution when considering resumption of ZYMFENTRA, and monitor patients closely.
HEPATOTOXICITY
Hepatobiliary disorders, including acute liver failure, jaundice abnormal hepatic function, hepatic steatosis, hepatitis, hepatotoxicity, hyperbilirubinemia, and non-alcoholic fatty liver, have been reported in patients receiving infliximab products post-marketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, ZYMFENTRA should be discontinued, and a thorough investigation of the abnormality should be undertaken.
CONGESTIVE HEART FAILURE
Cases of worsening congestive heart failure (CHF) and new onset CHF have been
reported with TNF blockers. Some cases had a fatal outcome. In several
exploratory trials of other TNF blockers in the treatment of CHF, there were
greater proportions of TNF-blocker-treated patients who had CHF exacerbations
requiring hospitalization or increased mortality. ZYMFENTRA has not been
studied in patients with a history of CHF and ZYMFENTRA should be used with
caution in patients with CHF.
HEMATOLOGIC REACTION
Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some
fatal) have been reported. The causal relationship to infliximab-product
therapy remains unclear. Exercise caution in patients who have ongoing or a
history of significant hematologic abnormalities. Advise patients to seek
immediate medical attention if they develop signs and symptoms of blood
dyscrasias or infection. Consider discontinuation of ZYMFENTRA in patients who
develop significant hematologic abnormalities.
HYPERSENSITIVITY AND OTHER ADMINISTRATION REACTIONS
In post-marketing experience, serious systemic hypersensitivity reactions
(including anaphylaxis, hypotension, and serum sickness) have been reported
following administration of infliximab products. If an anaphylactic or other
clinically significant hypersensitivity reaction occurs, institute appropriate
therapy and discontinue ZYMFENTRA.
INJECTION SITE REACTIONS
In clinical studies, localized injection-site reactions were reported following
administration of ZYMFENTRA. If a clinically significant injection-site
reaction occurs, institute appropriate therapy and discontinue ZYMFENTRA.
NEUROLOGIC REACTIONS
Agents that inhibit TNF have been associated with central nervous system (CNS)
manifestation of systemic vasculitis, seizure, and new onset or exacerbation of
CNS demyelinating disorders, including multiple sclerosis and optic neuritis,
and peripheral demyelinating disorders, including Guillain-Barré syndrome.
Exercise caution when considering ZYMFENTRA in patients with these disorders
and consider discontinuation if these disorders develop.
RISK OF INFECTION WITH CONCURRENT ADMINISTRATION OF OTHER
BIOLOGICS PRODUCTS
Serious infections and neutropenia have been reported with concurrent use of
ZYMFENTRA with other immunosuppressive biological products. The concurrent use
of ZYMFENTRA with other immunosuppressive biological products used to treat UC
and CD may increase the risk of infection and is not recommended.
RISK OF ADDITIVE IMMUNOSUPPRESSIVE EFFECTS FROM PRIOR
BIOLOGICAL PRODUCTS
Consider the half-life and mode of action of prior biological products to avoid
unintended additive immunosuppressive effects when initiating ZYMFENTRA.
AUTOIMMUNITY
Treatment with TNF blockers may result in the formation of autoantibodies and
in the development of a lupus-like syndrome. Discontinue ZYMFENTRA treatment if
symptoms of a lupus-like syndrome develop.
VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC
INFECTIOUS AGENTS
Prior to initiating ZYMFENTRA, update vaccinations in accordance with current
vaccination guidelines. Live vaccines or therapeutic infectious agents should
not be given with ZYMFENTRA due to the possibility of clinical infections,
including disseminated infections. At least a 6-month waiting period following
birth is recommended before the administration of any live vaccine to infants
exposed in utero to ZYMFENTRA.
ADVERSE REACTIONS
In clinical trials with ZYMFENTRA, the most common adverse reactions occurring in≥3% of ZYMFENTRA -treated patients included site reactions, COVID-19, anemia, arthralgia, infection site reaction, increased alanine aminotransferase and abdominal pain for UC, and COVID-19, headache, upper respiratory tract infection, injection site reaction, diarrhea, increased blood creatine phosphokinase, arthralgia, increased alanine aminotransferase, hypertension, urinary tract infection, neutropenia, dizziness and leukopenia for CD.
Please click for Full U.S.
Prescribing Information.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
References